Q-omics provides the consensus-scored ATP5PBP6 profile across patient tissues and cancer cell-line models. ATP5PBP6 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, ATP5PBP6 is differentially expressed in 5, with the highest sampling consensus in UCEC. Additionally, ATP5PBP6 RNA expression shows 6,431 significant protein co-abundance associations, with the highest sampling consensus in OV. Together, these results highlight LUAD, UCEC, and OV as cancer lineages where ATP5PBP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATP5PBP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATP5PBP6 survival associations across molecular data types. ATP5PBP6 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATP5PBP6 RNA expression–survival associations across cancer types. High ATP5PBP6 expression shows unfavorable associations in LUAD, LIHC and LGG, but favorable associations in READ, PAAD and COAD. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for ATP5PBP6 RNA expression.
This table summarizes ATP5PBP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for ATP5PBP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATP5PBP6 shows higher tumor expression in UCEC, COAD, LUAD, PRAD and LUSC. The UCEC box plot shows higher ATP5PBP6 RNA expression in tumor versus normal tissue (log2 FC = +0.196, t-test p = .037).
This table shows molecular features associated with ATP5PBP6 in patient tissues and cancer cell lines. In patient samples, ATP5PBP6 shows the broadest associations at the RNA and protein expression levels, with OV recurring as the lineage with the largest associated feature set.
